Bioxytran, Inc. (BIXT)
| Market Cap | 2.41M -65.5% |
| Revenue (ttm) | n/a |
| Net Income | -3.49M |
| EPS | -0.03 |
| Shares Out | 114.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,502 |
| Open | 0.0251 |
| Previous Close | 0.0249 |
| Day's Range | 0.0209 - 0.0251 |
| 52-Week Range | 0.0209 - 0.0949 |
| Beta | 1.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Bioxytran
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing... [Read more]
Financial Performance
Financial StatementsNews
Bioxytran Quarterly report: Q2 2026
Bioxytran has published its Q2 2026 quarterly earnings report on August 14, 2026.
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2...
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran's A-SUQAR commercial distribution agreement BOSTO...
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company d...
Bioxytran Quarterly report: Q1 2026
Bioxytran has published its Q1 2026 quarterly earnings report on May 15, 2026.
Bioxytran Annual report: Q4 2025
Bioxytran has published its Q4 2025 annual report on April 15, 2026.
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology c...
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, In...
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomize...
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, do...
Bioxytran Transcript: Noble Capital Markets’ Emerging Growth Virtual Equity Conference
A novel antiviral based on polysaccharide galectin antagonists showed rapid viral clearance in phase II trials, with no adverse effects and broad-spectrum potential. The company is pursuing both nutraceutical commercialization and drug approval, with additional pipeline assets in oxygen delivery for stroke.
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovi...
Bioxytran Transcript: Emerging Growth Conference 88
A clinical stage biotech is advancing three carbohydrate-based platforms targeting antivirals, stroke, and cancer metastasis, with a lead drug showing 100% viral reduction in trials. Top-line data is expected soon, and new partnerships are being pursued, including for immunotherapy and bird flu research.
Bioxytran Quarterly report: Q3 2025
Bioxytran has published its Q3 2025 quarterly earnings report on November 14, 2025.
Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
BOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer's, and v...
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pl...
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is pr...
Bioxytran Quarterly report: Q2 2025
Bioxytran has published its Q2 2025 quarterly earnings report on August 11, 2025.
Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT...
Bioxytran Transcript: Emerging Growth Conference 83
Three AI-driven platform technologies were showcased, including a broad-spectrum antiviral with strong clinical results, an oxygenation molecule leveraging camel hemoglobin, and a cancer metastasis treatment. The company highlighted undervaluation, ongoing licensing, and upcoming clinical and funding milestones.
Bioxytran Secures a Source of GMP Quality Camel Hemoglobin
- First use of camel hemoglobin as a universal oxygen carrier - Unique properties make it an ideal ingredient for oxygen transport BOSTON, MASSACHUSETTS, June 18, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, I...
Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes
Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments
Bioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge Submission
PHM23 was one of a handful of molecules chosen by the university Bird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSW...
Bioxytran Quarterly report: Q1 2025
Bioxytran has published its Q1 2025 quarterly earnings report on May 14, 2025.
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the ...